Susan Suchdev - Annexin Pharmaceuticals Chief Officer
| ANNX Stock | SEK 0.54 0.06 12.50% |
Insider
Susan Suchdev is Chief Officer of Annexin Pharmaceuticals AB
| Age | 51 |
| Phone | 46 7 09 65 16 65 |
| Web | https://www.annexinpharma.com/sv |
Annexin Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.568) % which means that it has lost $0.568 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.0595) %, meaning that it generated substantial loss on money invested by shareholders. Annexin Pharmaceuticals' management efficiency ratios could be used to measure how well Annexin Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Frida Lekander | BioArctic AB | N/A | |
| Magnus Corfitzen | Ascelia Pharma AB | 48 | |
| Gunilla Osswald | BioArctic AB | 62 | |
| Christer Mller | BioArctic AB | 64 | |
| Johanna Christensen | Cantargia AB | N/A | |
| Peter Madsen | Cantargia AB | N/A | |
| Harald Borgeke | BioArctic AB | N/A | |
| Joakim Arwidson | Biovica International AB | 55 | |
| Mattias Bergqvist | Biovica International AB | 53 | |
| Marcuss | Cantargia AB | N/A | |
| Tomas Andersson | Biovica International AB | 63 | |
| Kjell Sjstrm | Cantargia AB | N/A | |
| Dominique Tersago | Cantargia AB | 61 | |
| Despina Hedin | Ascelia Pharma AB | 37 | |
| Otti Gref | Biovica International AB | 55 | |
| Julie Brogren | Ascelia Pharma AB | 51 | |
| Carl MD | Ascelia Pharma AB | 60 | |
| Nina Valkama | Cantargia AB | N/A | |
| Ignacio GarciaRibas | Cantargia AB | N/A | |
| Cecilia Driving | Biovica International AB | 52 | |
| Warren Cresswell | Biovica International AB | 55 | |
Management Performance
| Return On Equity | -1.06 | |||
| Return On Asset | -0.57 |
Annexin Pharmaceuticals Leadership Team
Elected by the shareholders, the Annexin Pharmaceuticals' board of directors comprises two types of representatives: Annexin Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Annexin. The board's role is to monitor Annexin Pharmaceuticals' management team and ensure that shareholders' interests are well served. Annexin Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Annexin Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ulrika Harndahl, Head CMC | ||
| Anna MD, Chief Officer | ||
| Susan Suchdev, Chief Officer | ||
| Henrik Palm, Chief Officer | ||
| Anders MD, Chief Officer | ||
| MSc LLM, Therapy Ophthalmology |
Annexin Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Annexin Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.06 | |||
| Return On Asset | -0.57 | |||
| Current Valuation | 125.48 M | |||
| Shares Outstanding | 154.5 M | |||
| Shares Owned By Insiders | 45.17 % | |||
| Shares Owned By Institutions | 5.06 % | |||
| Price To Book | 4.90 X | |||
| EBITDA | (50.28 M) | |||
| Net Income | (52.14 M) | |||
| Cash And Equivalents | 22.77 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Annexin Stock Analysis
When running Annexin Pharmaceuticals' price analysis, check to measure Annexin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annexin Pharmaceuticals is operating at the current time. Most of Annexin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Annexin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annexin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Annexin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.